Loading...
•
Jun 30
LabCorp Q2 2025 Earnings Report
Labcorp delivered strong Q2 2025 results, achieving solid revenue growth and raising full-year guidance.
Key Takeaways
Labcorp reported strong Q2 2025 results with higher revenue and net income, driven by strong demand, new oncology test launches, and expanded partnerships with hospitals. The company raised its full-year revenue, EPS, and free cash flow guidance.
Revenue grew to $3.53 billion, driven by diagnostics and biopharma services
Net income increased to $237.9 million, with EPS of $2.84
Adjusted EPS reached $4.35, supported by higher operating income
Full-year guidance was raised across revenue, adjusted EPS, and free cash flow
LabCorp
LabCorp
LabCorp Revenue by Segment
Revenue by Segment
Diagnostics Revenue
CapyFin.comBiopharma Lab Services Revenue
CapyFin.com Forward Guidance
Labcorp raised its full-year 2025 revenue, adjusted EPS, and free cash flow guidance, citing strong organic demand and expanded partnerships.
Positive Outlook
- Raised enterprise revenue growth to 7.5%-8.6%
- Raised adjusted EPS guidance to $16.05-$16.50
- Raised free cash flow guidance to $1.13-$1.28 billion
- Strong organic demand in diagnostics and biopharma services
- Ongoing partnerships with hospitals and new oncology test launches
Challenges Ahead
- Adjusted operating margin constrained by Invitae
- Currency fluctuations impacted guidance
- Capital expenditures remain high for expansion
- Ongoing integration costs from acquisitions
- Competitive pressures in diagnostics market
Revenue & Expenses
Visualization of income flow from segment revenue to net income